Stockreport

Organon & Co (OGN) Q3 2025 Earnings Call Highlights: Strong Biosimilars Performance Amidst ... [Yahoo! Finance]

Organon & Co.  (OGN) 
PDF Adjusted Gross Margin: 60.3% for the third quarter. Women's Health Franchise: Declined 4% at constant currency; Nexplanon sales were $223 million. Biosimilars: Hadl [Read more]